SLU-PP-332 (Exercise Mimetic)

Q: Is SLU-PP-332 an actual exercise substitute, or does it just feel like you worked out?

SLU-PP-332 activates the same metabolic pathways exercise does (mitochondrial biogenesis, PGC-1α upregulation, AMPK activation), but it's not a complete substitute. It increases endurance 70% and reduces weight 12% without exercise, but it doesn't build muscles or improve cardiovascular fitness like real training does. Think of it as metabolic enhancement, not exercise replacement.

Q: Why does SLU-PP-332 work so much faster than training (12% weight loss in 28 days)?

Training requires weeks to upregulate mitochondrial genes; SLU-PP-332 activates them within hours. In mouse studies, energy expenditure increased 25% within 2 hours, creating sustained fat oxidation and rapid weight loss. This bypass of normal training adaptation pathways explains the speed, though long-term human data doesn't exist.

Q: Could SLU-PP-332 cause liver damage if used long-term?

The file flags SLU-PP-332 as potentially hepatotoxic. However, animal studies showed no liver damage at therapeutic doses. The flag exists because long-term human safety is unknown. If used experimentally, liver function tests (ALT, AST, bilirubin) should be monitored regularly.

Q: Is there an oral version of SLU-PP-332 in development?

Yes. SLU-PP-915 (a distinct oral bioavailable ERR pan-agonist) shows similar efficacy to SLU-PP-332 when given orally. A 2025 study found it enhanced aerobic performance as effectively as the injectable form. This represents major progress toward clinical translation, though human trials haven't started.

Synthetic Pan-ERR Agonist · Exercise Mimetic & Metabolic Modulator

Overview

Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.

12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.

Significantly improved glucose tolerance in obese mice with lower fasting glucose and insulin levels.

Increases resting energy expenditure by 25% for fatty acid oxidation within 2 hours.

Reduced hepatic steatosis, decreased hepatic triglycerides, and enhanced hepatic fatty acid oxidation.

Mechanism

12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.

Research areas

Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.
Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.
12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.
Significantly improved glucose tolerance in obese mice with lower fasting glucose and insulin levels.
Increases resting energy expenditure by 25% for fatty acid oxidation within 2 hours.
Reduced hepatic steatosis, decreased hepatic triglycerides, and enhanced hepatic fatty acid oxidation.
70% increase in running time and 45% increase in running distance in preclinical models.
Increased type IIa oxidative skeletal muscle fibers with enhanced oxidative capacity.
Improved ejection fraction in heart failure models with reduced cardiac fibrosis.
First compound to reverse age-related mitochondrial dysfunction in 21-month-old mice.
Reversed age-related albuminuria increase and prevented podocyte loss in elderly mice.

Research notes

Animal studies show favorable safety with no severe effects at therapeutic doses
Well-tolerated in rodents and canines
No liver, kidney, or cardiac toxicity documented
No lean mass loss
Does not suppress hormones or act as stimulant
Minor plasma cholesterol and liver enzyme changes in some studies
Severe hypoglycemia (especially with diabetes medications)
Any cardiovascular symptoms (chest pain, palpitations, shortness of breath)
Signs of liver dysfunction (jaundice, dark urine, severe abdominal pain)
Kidney problems (reduced urination, swelling, severe back pain)
Severe headaches or neurological symptoms
Allergic reactions (rash, hives, difficulty breathing, swelling)
NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications

References

FAQs

Is SLU-PP-332 an actual exercise substitute, or does it just feel like you worked out?

SLU-PP-332 activates the same metabolic pathways exercise does (mitochondrial biogenesis, PGC-1α upregulation, AMPK activation), but it's not a complete substitute. It increases endurance 70% and reduces weight 12% without exercise, but it doesn't build muscles or improve cardiovascular fitness like real training does. Think of it as metabolic enhancement, not exercise replacement.

Why does SLU-PP-332 work so much faster than training (12% weight loss in 28 days)?

Training requires weeks to upregulate mitochondrial genes; SLU-PP-332 activates them within hours. In mouse studies, energy expenditure increased 25% within 2 hours, creating sustained fat oxidation and rapid weight loss. This bypass of normal training adaptation pathways explains the speed, though long-term human data doesn't exist.

Could SLU-PP-332 cause liver damage if used long-term?

The file flags SLU-PP-332 as potentially hepatotoxic. However, animal studies showed no liver damage at therapeutic doses. The flag exists because long-term human safety is unknown. If used experimentally, liver function tests (ALT, AST, bilirubin) should be monitored regularly.

Is there an oral version of SLU-PP-332 in development?

Yes. SLU-PP-915 (a distinct oral bioavailable ERR pan-agonist) shows similar efficacy to SLU-PP-332 when given orally. A 2025 study found it enhanced aerobic performance as effectively as the injectable form. This represents major progress toward clinical translation, though human trials haven't started.